Skip to main content
main-content

17.05.2019 | Original Article

Exposure time versus cytotoxicity for anticancer agents

Zeitschrift:
Cancer Chemotherapy and Pharmacology
Autoren:
David M. Evans, Jianwen Fang, Thomas Silvers, Rene Delosh, Julie Laudeman, Chad Ogle, Russell Reinhart, Michael Selby, Lori Bowles, John Connelly, Erik Harris, Julia Krushkal, Larry Rubinstein, James H. Doroshow, Beverly A. Teicher
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00280-019-03863-w) contains supplementary material, which is available to authorized users.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose

Time is a critical factor in drug action. The duration of inhibition of the target or residence time of the drug molecule on the target often guides drug scheduling.

Methods

The effects of time on the concentration-dependent cytotoxicity of approved and investigational agents [300 compounds] were examined in the NCI60 cell line panel in 2D at 2, 3, 7 and in 3D 11 days.

Results

There was a moderate positive linear relationship between data from the 2-day NCI60 screen and the 3-, 7- and 11-day and a strong positive linear relationship between 3-, 7- and 11-day luminescence screen IC50s by Pearson correlation analysis. Cell growth inhibition by agents selective for a specific cell cycle phase plateaued when susceptible cells were growth inhibited or killed. As time increased the depth of cell growth inhibition increased without change in the IC50. DNA interactive agents had decreasing IC50s with increasing exposure time. Epigenetic agents required longer exposure times; several were only cytotoxic after 11 days’ exposure. For HDAC inhibitors, time had little or no effect on concentration response. There were potency differences amongst the three BET bromodomain inhibitors tested, and an exposure duration effect. The PARP inhibitors, rucaparib, niraparib, and veliparib reached IC50s < 10 μM in some cell lines after 11 days.

Conclusions

The results suggest that variations in compound exposure time may reflect either mechanism of action or compound chemical half-life. The activity of slow-acting compounds may optimally be assessed in spheroid models that can be monitored over prolonged incubation times.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary file1 (DOC 58 kb)
280_2019_3863_MOESM1_ESM.doc
Supplemental Figure 1. Median concentrations (micromolar, blue) and mean log IC50 concentrations (micromolar, red) for the NCI60 cell line panel after compound exposure for 2 days, 3 days, 7 days or 11 days for methotrexate, raltitrexed, doxorubicin, topotecan, belinostat, panobinostat, romidepsin and selinexor. Supplemental Figure 2A. Mean log IC50 concentrations for the NCI60 cell line panel after compound exposure for 2 days, 3 days, 7 days or 11 days for the EGFR inhibitor erlotinib (blue), the FAK inhibitor TAE-226, the MPS-1 inhibitor BAY-1217389 and for the Akt inhibitor MK-2206. 2B. Mean log IC50 concentrations for the NCI60 cell line panel after compound exposure for 2 days, 3 days, 7 days or 11 days for the BET bromodomain inhibitors MK8628, BET-BAY-002 and GSK-525762. 2C. Mean log IC50 concentrations for the NCI60 cell line panel after compound exposure for 2 days, 3 days, 7 days or 11 days for the IAP inhibitors birinapant and LCL-161. Supplemental Figure 3A. Concentration response curves in three representative NCI60 panel cell lines after compound exposure for 2 days (blue), 3 days (red), 7 days (yellow) or 11 days (green) for the cell surface transmembrane receptor tyrosine kinase inhibitors sorafenib, erlotinib, crizotinib and nintedanib. B. Concentration response curves in three representative NCI60 panel cell lines after compound exposure for 2 days (blue), 3 days (red), 7 days (yellow) or 11 days (green) for selected intracellular kinases: FAK inhibitors TAE-226, MPS-1 inhibitor BAY-1217389, and Akt inhibitor MK-2206 (PPTX 2132 kb)
280_2019_3863_MOESM2_ESM.pptx
Literatur
Über diesen Artikel
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise